GPCR: ADA Dinner With Management Highlighted by Exciting New Amylin Program Learnings; Ph 2a MAD (1H27E) a Potentially Transformational Catalyst

Research evidence excerpt

GPCR: ADA Dinner With Management Highlighted by Exciting New Amylin Program Learnings; Ph 2a MAD (1H27E) a Potentially Transformational Catalyst

details below; the ACCESS trial results were simultaneously published in Nature

Medicine (paper HERE; supplement HERE).

Market Data See our prior takeaways on the ACCESS study results:

52-Week Range $15.80 - $94.90

GPCR: Path to Ph 3 Cleared as Aleni Delivers Robust Weight Loss in ACCESS/ACCESS Shares Out (M) 71.1 •

II w/ Acceptable Tolerability from 5 mg; 2.5 mg Starting Dose Adds to Our Enthusiasm Market Cap (M) $2,671

GPCR: Gimme More! More Data, More Weight Loss, More Tolerability - Ph 2 Results ADV (3 mo; 000) 889 •

Firmly Establish Aleni’s Strategic 3rd-to-Market HIGHLY Scalable Oral GLP Position

GPCR

25.00 Volume (Millions) Price (USD) 100 Highlights from our conversation with management include palpable enthusiasm for

20.00 80 novel oral amylin portfolio

15.00 60 • ACCG-2671 preclinical data highlights ~60hr half-life in NHPs, setting up a

10.00 50 differentiated QD dosing profile with path to aleniglipron combos confirmed. GPCR

30 presented a poster on NHP data with oral small molecule DACRA, ACCG-2671, which 5.00

20 revealed three unique firsts for the molecule: (1) the half-life of 2671 was shown to be

0.00 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 10 ~60hrs in NHPs, comfortably supporting QD dosing in humans, in our view; (2) first time Price Volume Created by BlueMatrix

showing in monkeys the dose response for BW loss of up to 11% as a monotherapy;

and (3) first time combination data of aleniglipron and 2671 were shared, demonstrating

POC for an at-least-additive effect in NHPs. ACCG-2671 is currently in Ph 1, and the

co anticipates that SAD data will be available in 3Q26, where, along with ensuring there